Analyst Conference Summaries

Biotechnology Investor Aids

Regeneron Pharmaceuticals
REGN

conference date: February 2, 2024 @ 5:30 AM Pacific Time

Regeneron Pharmaceuticals Boosted by COPD Data [March 25, 2024 at Seeking Alpha]

Regeneron Priced Right For Long-Term Investors [September 27, 2019 at Seeking Alpha]

Regeneron: A Buy On Dupixent And Pipeline [August 15, 2018 at Seeking Alpha]

Regeneron Unknown: Eylea Future Competition Effects [May 17, 2018]

Analyst Conference Notes by William P. Meyers
2023
Regeneron
Q1 2023
Regeneron
Q2 2023
Regeneron
Q3 2023
Regeneron
Q4 2023
May 4, 2023 Aug. 3, 2023 Nov. 2, 2023 Feb. 2, 2024
2022
Regeneron
Q1 2022
missed Regeneron
Q3 2022
Regeneron
Q4 2022
May 4, 2022 Aug. 3, 2022 Nov. 3, 2022 Feb. 3, 2023
2021
Regeneron
Q1 2021
Regeneron
Q2 2021
Regeneron
Q3 2021
Regeneron
Q4 2021
May 6, 2021 Aug. 5, 2021 Nov. 4, 2021 Feb. 4, 2022
2020
Regeneron
Q1 2020
Regeneron
Q2 2020
Regeneron
Q3 2020
Regeneron
Q4 2020
May 5, 2020 Aug. 5, 2020 Nov. 5, 2020 Feb. 5, 2021
2019
Regeneron
Q1 2019
Regeneron
Q2 2019
Regeneron
Q3 2019
Regeneron
Q4 2019
May 7, 2019 August 6, 2019 Nov. 5, 2019 Feb. 6, 2019
2018
May 3, 2018
August 8, 2018
Nov. 6, 2018
Feb. 6, 2019
2017
May 4, 2017
August 3, 2017
Nov. 8, 2017
Feb. 8, 2018
2016
05/05/2016
08/04/2016
11/04/2016
02/09/2017
2015
05/07/2015
08/04/2015
11/04/2015
02/09/2016
2014
05/08/2014
08/05/2014
11/04/2014
02/10/2015
2013
not available

08/06/2013
11/05/2013
 02/11/2014

Regeneron (REGN) is a biotechnology company currently providing Eylea for Wet Macular Degeneration, Arcalyst for Cryopyrin-Associated Periodic Syndromes (CAPS), and Zaltrap for metastatic colorectal cancer.

Regeneron web site
Regeneron investor relations page

Note that I owned Regeneron stock from June 24, 2014 to January 10, 2017


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 CLDX
 CDTX
 FATE
 GILD
 GLYC
 INCY
 ILMN
 INO
 IONS
 MCHP
 MRNA
 PLX
 REGN
 RNA
 SANA
 SGEN
 SYRS
 VRTX
 VSTM
 WBA

     

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. These are my personal notes and serve as the basis of my Seeking Alpha articles.

Copyright 2023 William P. Meyers